

Inter-Assay Precision-Between-run precision was determined by replicate measurements of six different serum samples over a series of individually calibrated assays. Between-assay variability is shown below:

Serum Sample	1	2	3	4	5
# Replicates	20	26	26	26	26
Mean cTnI (ng/ml)	1.68	5.88	24.56	48.91	85.81
S.D.	0.11	0.28	1.14	2.23	3.76
C.V. (%)	6.7	4.8	4.7	4.6	4.4

4. **Specificity**-The following were tested for cross-reactivity at concentrations up to the levels indicated below. No cross-reactivity was observed for any of the components.

MATERIAL TESTED	TEST CONCENTRATION
Rabbit skeletal muscle troponin C	2,500 ng/ml
Human cardiac troponin T	2,500 ng/ml
Human skeletal muscle troponin T	2,500 ng/ml
Human skeletal muscle troponin I	2,500 ng/ml
Hemoglobin	1.2 g/dl
Bilirubin	20 mg/dl
Cholesterol	500 mg/dl
Triglyceride	1,000 mg/dl
Total Protein	10 /dl

5. **Recovery**-Various patient serum samples of known human cTnI levels were combined and assayed in duplicate. The mean recovery was 93.3%.

PAIR NO.	EXPECTED [cTnI] (ng/ml)	OBSERVED [cTnI] (ng/ml)	% RECOVERY
1	4.25	3.95	92.9%
2	8.97	8.50	94.8%
3	11.43	10.49	91.8%
4	14.97	14.00	93.5%
5	32.34	29.62	91.6%
6	32.77	30.49	93.0%
7	81.00	77.21	95.3%

REFERENCES

1. Etievent, J., Chocron, S., Toubin, G., et. al.: The use of cardiac troponin I as a marker of peri-operative myocardial ischemia. *Ann. Thorac. Surg.*, 59:1192-94, 1995.
2. Apple, F.: Acute Myocardial Infarction and Coronary Reperfusion: Serum Cardiac Markers for the 1990's. *Am. J. Clin. Path.*, 97: 217-26, 1992.
3. Adams, J., Bodor, G., Davila-Romain, V., et. al.: Cardiac troponin I: A marker for cardiac injury. *Circulation*, 88:101-6, 1993.
4. Corin S., Juhasz, O., Zhul, et. al.: Structure & expression of the human slow twitch skeletal muscle troponin I gene. *J. Bio. Chem.*, 269:10651-7, 1994.
5. Perry, S.V.: The regulation of contractile activity in Muscle. *Biochem. Soc. Trans.* 7:593, 1979.
6. William, J.M., and Grand, R.J.A.: Comparison of amino acid sequence of troponin I from different striated muscles. *Nature*, 271:31, 1978.
7. Mehegan, J.P., and Tobacman, L.S.: Cooperative interaction between troponin molecules bound to the cardiac thin filament. *J. Biol. Chem.*, 266:966, 1991.
8. Mair, J., Wagner, I., Puschendorf, B., et. al.: Cardiac troponin I to diagnose myocardial injury. *The Lancet*, 341:838-9, 1993.
9. Mair, J., Laruc, C., Mair, P., et. al.: Use of Cardiac Troponin I to Diagnose Perioperative Myocardial Infarction in Coronary Artery Bypass Grafting. *Clin. Chem.*, 40: 2066-70, 1994.
10. Vallins, W.J., et. al.: Molecular cloning of human cardiac troponin I using polymerase chain reaction. *FEBS Lett.*, 270:57, 1990.
11. Leszyk, J., Dumaswala, R., Potter, J.D., et. al.: Amino acid sequence of bovine cardiac troponin I. *Biochemistry*, 27: 2821-7, 1988.

2008-01-14 (Mfg. 050103)

Warning

All of BQ Kits ELISA kits have not been tested for clinical use and are not approved in the United States by the FDA for diagnostic clinical use. They are components or reagents made solely for research use, further manufacturing and export use. It is the commitment of BQ Kits customers to receive its products solely for the purpose of exportation or research, and not for the purposes of clinical diagnostic use.

BQ KITS, INC. DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THESE PRODUCTS. IN PARTICULAR BQ KITS, INC. DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY PRODUCT

BQ Kits

Troponin I ELISA

Catalog No. BQ 015C (96 Tests)

INTENDED USE

The cTnI ELISA is intended for the quantitative determination of cardiac troponin I in human serum. Measurement of troponin I values are useful in the evaluation of acute myocardial infarction (AMI).

SUMMARY AND EXPLANATION

Troponin is the inhibitory or contractile regulating protein complex of striated muscle. It is located periodically along the thin filament of the muscle and consists of three distinct proteins: troponin I, troponin C, and troponin T. Likewise, the troponin I subunit exists in three separate isoforms; two in fast-twitch and slow-twitch skeletal muscle fibers, and one in cardiac muscle. The cardiac isoform (cTnI) is about 40% dissimilar, has a molecular weight of 22,500 daltons, Cardiac troponin I (cTnI) has been useful in the differential diagnosis of patients presenting to Emergency Departments (ED) with chest pain 18-20. Myocardial infarction is diagnosed when blood levels of sensitive and specific biomarkers, such as cardiac troponin, the MB isoenzyme of creatine kinase (CK-MB), and myoglobin, are increased in a clinical setting of acute ischemia. The most recently described and preferred biomarker for myocardial damage is cardiac troponin (I or T). The cardiac troponins exhibit myocardial tissue specificity and high sensitivity. The level of cTnI remains elevated for a much longer period of time (6-10 days), thus providing for a longer window of detection of cardiac injury. Normal levels of cTnI in the blood are very low. After the onset of an AMI, cTnI levels increase substantially and are measurable in serum within 4 to 6 hours, with peak concentrations reached in approximately 12 to 24 hours after infarction. The cTnI Enzyme Immunoassay provides a rapid, sensitive, and reliable assay for the quantitative measurement of cardiac-specific troponin I. The antibodies developed for the test will determine a minimal concentration of 1.0 ng/ml, and there is no cross-reactivity with human cardiac or skeletal troponin T or I.

PRINCIPLE OF ASSAY

The cTnI ELISA test is based on the principle of a solid phase ELISA. The assay system utilizes four unique monoclonal antibodies directed against distinct antigenic determinants on the molecule. Three mouse monoclonal anti-troponin I antibodies are used for solid phase immobilization (on the microtiter wells). The fourth antibody is in the antibody-enzyme conjugate solution. The test sample is allowed to react simultaneously with the four antibodies, resulting in the troponin I molecules being sandwiched between the solid phase and enzyme-linked antibodies. After a 90-minute incubation at room temperature, the wells are washed with water to remove unbound-labeled antibodies. A solution of (TMB) is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution changing the color to yellow. The concentration of troponin I is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.

Materials Provided	96 TESTS
1. Microwells coated with mouse Anti-TnI	12x8x1
2. Reference Standard Set	1 ml
3. cTnI Enzyme Conjugate Reagent	13 ml
4. TMB Reagent	11 ml
5. Stop Solution	11 ml

MATERIALS NOT PROVIDED

1. Distilled or deionized water
2. Precision pipettes
3. Disposable pipette tips
4. ELISA reader capable of reading absorbance at 450 nm
5. Absorbance paper or paper towel
6. Graph paper

STORAGE AND STABILITY

1. Store the kit at 2-8° C.
2. Keep microwells sealed in a dry bag with desiccants.
3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light.

WARNINGS AND PRECAUTIONS

1. Potential biohazardous materials:
The calibrator and controls contain human source components, which have been tested and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents. However, there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent. These reagents should be handled at the Biosafety Level 2, as recommended in the Centers for Disease Control/National Institutes of Health manual, "Biosafety in Microbiological and Biomedical Laboratories" 1984.
2. This kit is designed for Research Use Only.
3. Optimal results will be obtained by strict adherence to the test protocol. Precise pipetting as well as following the exact time and temperature requirements is essential.
4. Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.
5. The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed.
6. Control sera and sample diluent contain preserved with sodium azide. Sodium azide may react with lead and copper plumbing to form explosive metal azide. On disposal, flush with a large volume of water.

SPECIMEN COLLECTION AND PREPARATION

1. The use of SERUM samples is required for this test.
2. Specimens should be collected using standard venipuncture techniques. Remove serum from the coagulated or packed cells *within 60 minutes* after collection.
3. Specimens which cannot be assayed within 24 hours of collection should be frozen at -20°C or lower, and will be stable for up to six months.
4. Avoid grossly hemolytic (bright red), lipemic (milky), or turbid samples (after centrifugation).
5. Specimens should not be repeatedly frozen and thawed prior to testing. DO NOT store in "frost free" freezers, which may cause occasional thawing. Specimens which have been frozen, and those which are turbid and/or contain particulate matter, must be centrifuged prior to use.

REAGENT PREPARATION

1. All reagents should be allowed to reach room temperature (18-26°C) before use.
2. Reconstitute each lyophilized standard with 1.0 ml distilled water. Allow the reconstituted material to stand for at least 20 minutes and mix gently. The Reconstituted standards will be stable for up to 8 hours when stored sealed at 2-8°C. Discard the reconstituted Standards after 8 hours. To assure maximum stability of the reconstituted Standards, they should be aliquoted and frozen (-20°C or below) immediately after reconstitution has been achieved. Each aliquoted Standard should be frozen and thawed only once.
3. Samples with expected Troponin I concentrations over 100 ng/ml may be quantitated by dilution with diluent available from vender.

ASSAY PROCEDURE

1. Secure the desired number of coated wells in holder.
2. Dispense 100 µl of standards, specimens, and controls into appropriate wells.
3. Dispense 100 µl of Enzyme Conjugate Reagent into each well.
4. Thoroughly mix for 30 seconds. It is very important to mix completely.
5. Incubate at room temperature (18-25°C) for 90 minutes.
6. Remove the incubate mixture by flicking plate contents into a waste container.
7. Rinse and flick the microtiter wells 5 times with distilled or deionized water. (Please do not use tap water.)
8. Strike the wells sharply onto absorbent paper or paper towels to remove all residual water droplets.
9. Dispense 100 µl of TMB Reagent into each well. Gently mix for 5 seconds.
10. Incubate at room temperature for 20 minutes.
11. Stop the reaction by adding 100 µl of Stop Solution to each well.
12. Gently mix for 30 seconds. It is important to make sure that all the blue color changes to yellow color completely.
13. Read absorbance at 450nm with a microtiter well reader within 15 minutes.

CALCULATIONS OF RESEULTS

1. Calculate the mean absorbance value (OD450) for each set of reference standards, controls and samples.
2. Construct a standard curve by plotting the mean absorbance obtained for each reference standard against its concentration in ng/ml on graph paper, with absorbance on the vertical (y) axis and concentration on the horizontal (x) axis.
3. Using the mean absorbance value for each sample, determine the corresponding concentration of troponin I (ng/ml) from the standard curve. Depending on experience and/or the availability of computer capability, other methods of data reduction may be employed.
4. Patient samples with cTnI concentrations greater than 100 ng/ml should be diluted 10-fold with vender's Troponin I Sample Diluent. The final cTnI results in ng/ml.

Example of a Standard Curve

Results of a typical standard run with absorbency readings at 450nm on the Y axis against troponin I concentrations shown on the X axis. **NOTE:** This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each laboratory must provide its own data and standard curve in each experiment.

cTnI (ng/ml)	Absorbance (450nm)
0	0.048
2.0	0.110
7.5	0.307
30	1.357
75	2.853

EXPECTED VALUES

It is recommended that each laboratory establish its own normal ranges based on a representative sampling of the local population; however, the following values may be used as initial guideline range only. Two-hundred and twenty-five (225) apparently healthy adults were assayed using the test to establish the normal expected value, which was determined to be ≤0.5 ng/ml cTnI. All values from the normal population tested were below the sensitivity level of the assay (1.0 ng/ml).

LIMITATIONS OF THE PROCEDURE

1. Reliable and reproducible results will be obtained when the assay procedure is carried out with a complete understanding of the package insert instructions and with adherence to good laboratory practice.
2. Diagnostic results obtained from the cTnI ELISA should be used in conjunction with other diagnostic procedures and information available to the physician.; e.g., additional clinical testing, ECG, symptoms, and clinical observations.
3. Serum samples demonstrating gross lipemia, gross hemolysis, or turbidity should not be used with this test.
4. The wash procedure is critical. Insufficient washing will result in poor precision and falsely elevated absorbance readings.
5. Patient samples may contain human anti-mouse antibodies (HAMA) which are capable of giving falsely elevated or depressed results with assays that utilize mouse monoclonal antibodies. The vender's cTnI ELISA assay has been designed to minimize interference from HAMA-containing specimens; nevertheless complete elimination of this interference from all patient specimens cannot be guaranteed.
6. Test results that are inconsistent with the clinical picture and patient history should be interpreted with caution.

PERFORMANCE CHARACTERISTICS

1. **Sensitivity**-The minimum detectable concentration of the cTnI ELISA assay as measured by 2SD from the mean of a zero standard is estimated to be 1.0 ng/ml. Additionally, the functional sensitivity was determined to be 0.75 ng/ml ((as determined with inter-assay %C.V. ≤10%). Lower limit of cTnI ELISA = 0.48 ng/ml cTnI; upper limit = 1.0 ng/ml cTnI.
2. **Hook Effect**-No hook effect was observed in this assay at cardiac troponin-I concentrations up to 10,000 ng/ml.
3. **Precision**

Intra-Assay Precision-Within-run precision was determined by replicate determinations of seven different serum samples in one assay. Within-assay variability is shown below:

Serum Sample	1	2	3	4	5
# Repts.	20	20	20	20	20
Mean cTnI (ng/ml)	1.69	5.93	24.3	44.9	89.8
S.D.	0.05	0.22	1.35	1.78	2.52
C.V. (%)	2.8	3.7	5.6	4.0	2.8